AUA 2018: Prostate Biopsy Centralization at High Volume, Tertiary Care Centers Represents the Most Refined Diagnostic Tool for Prostate Cancer Patients
San Francisco, CA (UroToday.com) In an increasingly individualized prostate cancer (PCa) care, discordance between prostate biopsy and radical prostatectomy (RP) should be minimal. In tertiary care centers prostate biopsies may be performed more accurately due to adherence to strict protocols. In this study the authors aimed to evaluate the impact of centralized biopsy on PCa diagnostic accuracy.
AUA 2018: The German Risk-Adapted Prostate Cancer Screening Trial (PROBASE) – First Results After Recruitment of 30,000 Men
San Francisco, CA (UroToday.com) Population-based PSA screening is a controversial issue. A risk-adapted approach using a baseline PSA value at age 45 may improve the number needed to screen and to treat. The German risk-adapted PCa screening trial PROBASE is currently the largest ongoing screening trial and aims to accrue 50,000 men within 5 yrs in a prospective and randomized fashion. The trial opened in April 2014.
AUA 2018: The Association Between Physician Trust and Prostate Specific Antigen Screening: Implications for Shared Decision Making
San Francisco, CA (UroToday.com) Most cancer organizations recommend shared decision making for PSA screening, a process relying on a trusting relationship between patient and physician. The objective of this study was to assess the degree to which an individual’s trust in cancer information from their physician compared to internet based information, impacts the likelihood of receiving PSA-screening.
AUA 2018: PROSPER Study Results: Impact of Enzalutamide on Pain and Health-Related Quality of Life in Men with nmCRCP
San Francisco, CA (UroToday.com) The PROSPER trial (NCT02003924) compared the efficacy and safety of enzalutamide (ENZA) 160 mg/day vs placebo (PBO) in asymptomatic men with non-metastatic castration-resistant prostate cancer with prostate-specific antigen doubling time of 10 months. Patients were randomized 2:1. The study showed a statistically significant improvement in metastasis-free survival (MFS) with ENZA vs PBO. PROSPER also prospectively evaluated health-related quality of life (HRQoL) and pain.
AUA 2018: Cardiovascular Events and Biomarkers in a Randomized Trial Comparing LHRH Agonist and Antagonist Among Patients with Advanced Prostate Cancer
San Francisco, CA (UroToday.com) Androgen-deprivation therapy (ADT) used in prostate cancer patients may increase their risk of cardiovascular events. There has been data suggesting that LHRH-antagonist may be associated with lower risk of these events compared to LHRH agonists. The authors hypothesized a role for FSH in mediating ADT induced atherosclerosis. In this current presentation, the authors report biomarkers of cardio-vascular events and outcomes from a randomized controlled study.
AUA 2018: The Effectiveness and Safety of Cabazitaxel in Patients with mCRPC in Routine Clinical Practice: Results of CAPRISTANA
San Francisco, CA (UroToday.com) Cabazitaxel (CBZ) is approved for patients with mCRPC previously treated with docetaxel. This study reports on the observed effectiveness and safety of CBZ in routine clinical practice.
AUA 2018: Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial
San Francisco, CA (UroToday.com) The multicentric prospective Local treatment of Metastatic Prostate cancer (LoMP) trial investigates the role of cytoreductive radical prostatectomy (cRP) in addition to standard of care (SoC) for patients with newly diagnosed metastatic prostate cancer (mPC). The authors evaluated clinical outcomes and prognostic factors.